Login to Your Account

AAN Roundup

Monday, April 18, 2011
Opexa Therapeutics Inc., of The Woodlands, Texas, reported efficacy data showing that Tovaxin, a T-cell therapy for multiple sclerosis (MS), demonstrated a significant improvement in annualized relapse rate (ARR) compared to placebo in treatment-naïve patients in the Phase IIb TERMS study. In patients who had at least one relapse in the 12 months prior to enrolling in the study and who had no previous exposure to MS therapy, Tovaxin reduced the ARR by 64 percent vs. placebo (p = 0.046).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription